(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Figure out how to Separate Among Fledgling and Master Fender bender Legal counselors - 2Fireballs and a full moon. Here’s how to see two celestial events this week
- 3Flu cases are rising with a strain that makes older people sicker
- 4Unusual 'ingredients' helped stars form in a galaxy near the Milky Way
- 5Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- The architect of Iran’s military survival remains defiant
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- Korean Air takes emergency action as fuel prices soar
- Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- What do scientists hope to learn from NASA's historic Artemis 2 moon flyby?
- Starfront Observatories: A haven for distant stargazers
- Very good quality Greens All over The Planet
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Find the Native Culinary Customs: Local Flavors
